The platelet derived growth factor-B polymorphism is associated with risk of severe fever with thrombocytopenia syndrome in Chinese individuals
Metrics: PDF 1391 views | HTML 1583 views | ?
Xiao-Ai Zhang1, Chen-Tao Guo2, Qing-Bin Lu3, Jian-Gong Hu1, Ning Cui4, Zhen-Dong Yang4, Wei Peng5, Rong Liu1, Chun-Yan Hu1, Shu-Li Qin4, Xian-Jun Wang6, Shu-Jun Ding6, Dou-Dou Huang1,2, Wei Liu1,2, Wu-Chun Cao1
1State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, P. R. China
2Graduate School of Anhui Medical University, Hefei, 230032, P. R. China
3School of Public Health, Peking University, Beijing, 100191, P. R. China
4The 154 Hospital, People’s Liberation Army, Xinyang, 464000, P. R. China
5The Shangcheng People’s Hospital, Xinyang, 464000, P. R. China
6Shandong Provincial Center for Disease Control and Prevention, Jinan, 250001, P. R. China
Wu-Chun Cao, email: email@example.com
Wei Liu, email: firstname.lastname@example.org
Keywords: severe fever with thrombocytopenia syndrome, polymorphism, susceptibility, PDGF-B, cytokines
Received: December 06, 2015 Accepted: April 11, 2016 Published: April 27, 2016
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by a novel bunyavirus named SFTS virus (SFTSV). We hypothesize that host genetic variations may contribute to susceptibility to SFTS.
Results: Compared with the rs1800818 AA genotype, AG + GG genotypes were significantly associated with increased susceptibility to SFTS (odds ratio, 1.66, 95% confidence interval = 1.28-2.16; P < 0.001). By using the ELISA assay, we observed that PDGF-BB concentration was significantly reduced in acute phase of patients than in the controls (P < 0.001) and recovered patients at 6 month (P = 0.007) and 12 month (P = 0.003). A persistently reduced PDGF-BB was also revealed from the SFTSV-infected C57BL/6J mice (P < 0.001). The rs1800818 G allele was associated with decreased serum PDGF-BB levels in SFTS patients at their early infection (P = 0.015). In accordance, the relative mRNA levels of the at-risk G allele of 1800818 were lower than those of the A allele in heterozygous cell from acute phase of SFTS patients. PDGF-B rs1800818 conferred no susceptibility to severe or fatal outcome in SFTS patients.
Materials and Methods: An initially small-scale case-control association study guided the selection of platelet derived growth factor-B (PDGF-B) rs1800818 in 1020 SFTS patients and 1353 controls. Functional analyses were conducted to verify the biological significance of rs1800818 polymorphism.
Conclusions: Our findings suggest that the PDGF-B rs1800818 polymorphism might play a role in mediating the susceptibility to SFTS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.